Breast Cancer Coverage from Every Angle

Search for Optimal Dose of Nab-paclitaxel for Older Patients With Advanced Breast Cancer

By: Julia Fiederlein
Posted: Monday, October 5, 2020

There are limited data available regarding the safety and efficacy of treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in older patients with advanced breast cancer. As a result, Giuseppe Mottino, MD, of AUSL Toscana Centro, Prato, Italy, and colleagues conducted a study to identify the optimal weekly dose of nab-paclitaxel for this population. The results of the multicenter phase II EFFECT trial were published in Breast Cancer Research.

“Weekly taxanes are a suitable treatment option for older patients with metastatic breast cancer,” the investigators commented. “Whilst solvent-based paclitaxel and solvent-based docetaxel are established options, the EFFECT trial has evaluated [the] role of weekly nab-paclitaxel in this selected population, identifying 100 mg/m2 on days 1, 8, and 15 on a 28-day cycle as an effective and well-tolerated dose.”

The study included a total of 160 patients with advanced breast cancer. To be enrolled, the patients must have been at least 65 years of age. In a 1:1 allocation ratio, they were randomly assigned to receive either 100 mg/m2 (arm A) or 125 mg/m2 (arm B) of first-line weekly nab-paclitaxel. Follow-up data were provided for a median of 32.6 months.

A total of 140 events were reported in 158 evaluable patients. The median event-free survival times in arms A and B were 8.2 (P = .188) and 8.3 (P = .078) months, respectively. Similar progression-free survival, overall survival, and response rates were observed in both groups. Patients in arm A experienced lower rates of dose reduction (39% vs. 58%) and treatment discontinuation due to adverse events (14% vs. 28%) than those in arm B. Grade 2 to 3 fatigue (arm A vs. B, 43% vs. 51%, respectively) and peripheral neuropathy (arm A vs. B, 19% vs. 38%, respectively) were among the most commonly reported nonhematologic adverse events.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.